

Gunnar Juliusson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6181697/publications.pdf>

Version: 2024-02-01

65
papers

3,200
citations

279798

23
h-index

161849

54
g-index

65
all docs

65
docs citations

65
times ranked

5738
citing authors

#	ARTICLE	IF	CITATIONS
1	A risk score based on real-world data to predict early death in acute promyelocytic leukemia. <i>Haematologica</i> , 2022, 107, 1528-1537.	3.5	12
2	Regional differences in treatment and outcome for myeloma patients in Sweden: A population based Swedish myeloma register study. <i>Cancer Reports</i> , 2022, 5, e1614.	1.4	1
3	Venetoclax with intensive chemotherapy in younger patients with acute myeloid leukaemia. <i>Lancet Haematology</i> , 2022, 9, e317-e318.	4.6	0
4	Combinatorial molecule screening identified a novel diterpene and the BET inhibitor CPI-203 as differentiation inducers of primary acute myeloid leukemia cells. <i>Haematologica</i> , 2021, 106, 2566-2577.	3.5	6
5	Impact of treatment delay in acute myeloid leukemia revisited. <i>Blood Advances</i> , 2021, 5, 787-790.	5.2	14
6	Mutational spectrum of de novo NPM1-mutated acute myeloid leukemia patients older than 75 years. <i>Leukemia and Lymphoma</i> , 2021, 62, 1958-1966.	1.3	2
7	Is there an impact of measurable residual disease as assessed by multiparameter flow cytometry on survival of AML patients treated in clinical practice? A population-based study. <i>Leukemia and Lymphoma</i> , 2021, 62, 1973-1981.	1.3	4
8	Venetoclax and azacitidine combination in chemotherapy ineligible untreated patients with therapy-related myeloid neoplasms, antecedent myelodysplastic syndromes, or myelodysplastic/myeloproliferative neoplasms.. <i>Journal of Clinical Oncology</i> , 2021, 39, 7011-7011.	1.6	3
9	Hairy cell leukemia and COVID-19 adaptation of treatment guidelines. <i>Leukemia</i> , 2021, 35, 1864-1872.	7.2	28
10	Socioeconomic cost of AML in Sweden – A population-based study using multiple nationwide registers. <i>EJHaem</i> , 2021, 2, 385-393.	1.0	0
11	Epidemiology and Etiology of AML. <i>Hematologic Malignancies</i> , 2021, , 1-22.	0.2	3
12	Subcutaneous cladribine to treat multiple sclerosis: experience in 208 patients. <i>Therapeutic Advances in Neurological Disorders</i> , 2021, 14, 1756286421110576.	3.5	5
13	A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (R _{Ve} , G _{Ve} , G _{IVe}) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial. <i>Blood</i> , 2021, 138, 71-71.	1.4	36
14	Decreasing early mortality in acute myeloid leukaemia in Sweden 1997–2014: improving performance status is a major contributing factor. <i>British Journal of Haematology</i> , 2020, 188, 187-191.	2.5	7
15	Subclonal patterns in follow-up of acute myeloid leukemia combining whole exome sequencing and ultrasensitive IBSAFE digital droplet analysis. <i>Leukemia and Lymphoma</i> , 2020, 61, 2168-2179.	1.3	7
16	Introducing patient-reported outcome in the acute leukemia quality registries in Sweden. <i>European Journal of Haematology</i> , 2020, 104, 571-580.	2.2	3
17	Clonal competition within complex evolutionary hierarchies shapes AML over time. <i>Nature Communications</i> , 2020, 11, 579.	12.8	21
18	The prognostic impact of FLT3-ITD and NPM1 mutation in adult AML is age-dependent in the population-based setting. <i>Blood Advances</i> , 2020, 4, 1094-1101.	5.2	44

#	ARTICLE	IF	CITATIONS
19	Hypo, Hyper, or Combo: new paradigm for treatment of acute myeloid leukemia in older people. <i>Haematologica</i> , 2020, 105, 249-251.	3.5	4
20	Chromosomal Abnormalities and Prognosis in <i>NPM1</i> -Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International Cohorts. <i>Journal of Clinical Oncology</i> , 2019, 37, 2632-2642.	1.6	77
21	Targetable genetic alterations of <i>TCF4</i> (<i>E2-2</i>) drive immunoglobulin expression in diffuse large B cell lymphoma. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	51
22	Improved survival of men 50 to 75 years old with acute myeloid leukemia over a 20-year period. <i>Blood</i> , 2019, 134, 1558-1561.	1.4	38
23	Secondary Acute Myeloid Leukemia and the Role of Allogeneic Stem Cell Transplantation in a Population-Based Setting. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1770-1778.	2.0	25
24	Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology. <i>Blood Cancer Journal</i> , 2019, 9, 1.	6.2	40
25	Subpopulations of T Regulatory Cells in Blood Stem Cell Harvests Influence Development of Acute Graft Versus Host Disease in Allogeneic Transplant Recipients. <i>Cytometry Part B - Clinical Cytometry</i> , 2018, 94, 264-269.	1.5	6
26	Outcome and survival of myeloma patients diagnosed 2008–2015. Real-world data on 4904 patients from the Swedish Myeloma Registry. <i>Haematologica</i> , 2018, 103, 506-513.	3.5	103
27	Isolated myelosarcoma is characterized by recurrent <i>NFE2</i> mutations and concurrent preleukemic clones in the bone marrow. <i>Blood</i> , 2018, 131, 577-581.	1.4	14
28	Acute myeloid leukemia in very old patients. <i>Haematologica</i> , 2018, 103, e578-e580.	3.5	17
29	AML Xenografts Undergo Extensive Clonal Competition and Unmask Rare Clones in Patient Samples. <i>Blood</i> , 2018, 132, 2621-2621.	1.4	0
30	Incidence and prognostic significance of isolated trisomies in adult acute myeloid leukemia: A population-based study from the Swedish AML registry. <i>European Journal of Haematology</i> , 2017, 98, 493-500.	2.2	14
31	Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. <i>Blood</i> , 2017, 129, 553-560.	1.4	193
32	Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia. <i>Blood</i> , 2017, 130, 1713-1721.	1.4	170
33	Agonistic targeting of TLR1/TLR2 induces p38 MAPK-dependent apoptosis and NF- κ B-dependent differentiation of AML cells. <i>Blood Advances</i> , 2017, 1, 2046-2057.	5.2	35
34	A single-arm, open-label, phase 2 clinical trial evaluating disease response following treatment with BI-505, a human anti-intercellular adhesion molecule-1 monoclonal antibody, in patients with smoldering multiple myeloma. <i>PLoS ONE</i> , 2017, 12, e0171205.	2.5	39
35	Improved minimal residual disease detection by targeted quantitative polymerase chain reaction in <i>Nucleophosmin 1</i> type a mutated acute myeloid leukemia. <i>Genes Chromosomes and Cancer</i> , 2016, 55, 750-766.	2.8	12
36	ATM mutations in major stereotyped subsets of chronic lymphocytic leukemia: enrichment in subset #2 is associated with markedly short telomeres. <i>Haematologica</i> , 2016, 101, e369-e373.	3.5	16

#	ARTICLE	IF	CITATIONS
37	Prognostic impact of epigenetic classification in chronic lymphocytic leukemia: The case of subset #2. <i>Epigenetics</i> , 2016, 11, 449-455.	2.7	21
38	Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations. <i>Blood</i> , 2016, 127, 1007-1016.	1.4	130
39	Acute Myeloid Leukemia in Adolescents and Young Adults Treated in Pediatric and Adult Departments in the Nordic Countries. <i>Pediatric Blood and Cancer</i> , 2016, 63, 83-92.	1.5	16
40	UGT2B17 expression: a novel prognostic marker within IGHV-mutated chronic lymphocytic leukemia?. <i>Haematologica</i> , 2016, 101, e63-e65.	3.5	21
41	Small molecule screen identifies differentiation-promoting compounds targeting genetically diverse acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2016, 175, 342-346.	2.5	5
42	Monitoring Minimal Residual Disease in AML By Patient Specific Mutational Fingerprint Using Multiplex PCR and Deep Sequencing. <i>Blood</i> , 2016, 128, 1715-1715.	1.4	0
43	Mutational and Clonal Dynamics in Patient-Derived Xenografts of Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 1154-1154.	1.4	0
44	Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: a report from the Swedish Acute Leukemia Registry. <i>American Journal of Hematology</i> , 2015, 90, 208-214.	4.1	202
45	Prognostic significance of high hyperdiploid and triploid/tetraploid adult acute myeloid leukemia. <i>American Journal of Hematology</i> , 2015, 90, 800-805.	4.1	19
46	Functional loss of μ leads to NF- κ B deregulation in aggressive chronic lymphocytic leukemia. <i>Journal of Experimental Medicine</i> , 2015, 212, 833-843.	8.5	85
47	A pragmatic approach to dealing with fingolimod-related lymphopaenia in Europe. <i>Multiple Sclerosis and Related Disorders</i> , 2015, 4, 83-84.	2.0	7
48	Antagonistic Human Fc γ RIIB (CD32B) Antibodies Have Anti-Tumor Activity and Overcome Resistance to Antibody Therapy In Vivo. <i>Cancer Cell</i> , 2015, 27, 473-488.	16.8	108
49	Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 10786-10791.	7.1	92
50	Comprehensive Prospective Next Generation Sequencing of Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 3830-3830.	1.4	2
51	Reasons for Decreasing Early Mortality in Acute Myeloid Leukemia: An Epidemiological Study from the Swedish Acute Leukemia Registry. <i>Blood</i> , 2015, 126, 3748-3748.	1.4	0
52	Prevalence and Characteristics of Survivors from Adult Acute Myeloid Leukemia (AML) in Sweden 2014. <i>Blood</i> , 2015, 126, 4888-4888.	1.4	0
53	EGR2 Mutations in Chronic Lymphocytic Leukemia: A New Bad Player. <i>Blood</i> , 2015, 126, 4126-4126.	1.4	0
54	A genome-wide association study identifies multiple susceptibility loci for chronic lymphocytic leukemia. <i>Nature Genetics</i> , 2014, 46, 56-60.	21.4	166

#	ARTICLE	IF	CITATIONS
55	Novel Gene Mutations In Chronic Lymphocytic Leukemia: Prevalence and Clinical Implications In A Series Of 3185 Cases - Initial Results From The European Research Initiative On CLL. Blood, 2013, 122, 1614-1614.	1.4	0
56	Acute myeloid leukemia in the real world: why population-based registries are needed. Blood, 2012, 119, 3890-3899.	1.4	249
57	Older Patients With Acute Myeloid Leukemia Benefit From Intensive Chemotherapy: An Update From the Swedish Acute Leukemia Registry. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, S54-S59.	0.4	71
58	Hairy cell leukemia: epidemiology, pharmacokinetics of cladribine, and long-term follow-up of subcutaneous therapy. Leukemia and Lymphoma, 2011, 52, 46-49.	1.3	49
59	Hematopoietic stem cell transplantation rates and long-term survival in acute myeloid and lymphoblastic leukemia. Cancer, 2011, 117, 4238-4246.	4.1	51
60	“Hairy” cells: where are the roots of this leukemia?. Leukemia and Lymphoma, 2011, 52, 2205-2206.	1.3	0
61	Does Heparin Have An Anti-Myeloma Effect? An Analysis On Individual Data From Three Randomized Studies of GIMEMA, Nordic and Turkish Myeloma Study Groups,. Blood, 2011, 118, 3970-3970.	1.4	0
62	Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood, 2009, 113, 4179-4187.	1.4	811
63	LPL Is the Strongest Prognostic Factor in a Comparative Study of RNA-Based Markers in Chronic Lymphocytic Leukemia.. Blood, 2009, 114, 1254-1254.	1.4	4
64	Melphalan-Prednisone-Thalidomide to Newly Diagnosed Patients with Multiple Myeloma: A Placebo Controlled Randomised Phase 3 Trial.. Blood, 2007, 110, 78-78.	1.4	37
65	Screening for Copy Number Alterations and Loss of Heterozygosity in Chronic Lymphocytic Leukemia - A Comparative Study of Four Differently Designed, High Resolution Microarray Platforms.. Blood, 2007, 110, 2084-2084.	1.4	4